GlassScriptPhysician profile
Nusrat Jahan
NPI 1083046007
$15,448.04
in general payments reported to CMS, 2019-2025
29 companies · $8,986 in 2025
The $8,986 reported for 2025 was more than what 80% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,974 · 2020: $200 · 2021: $316 · 2022: $261 · 2023: $492 · 2024: $3,219 · 2025: $8,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,460 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,700 · Food and Beverage: $807 · Grant: $350 · Long Term Medical Supply Or Device Loan: $299 · Education: $80.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,460.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,700.00 |
| Food and Beverage | $807.38 |
| Grant | $350.00 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $80.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,249.13 | 2019-2025 | Enhertu |
| Pfizer INC. | $3,744.77 | 2025 | |
| Daiichi Sankyo INC. | $3,284.87 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $760.67 | 2019-2025 | |
| Amgen INC. | $275.37 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $218.06 | 2019-2021 | |
| Lilly USA, LLC | $216.16 | 2022-2025 | Verzenio |
| Astellas Pharma US INC | $213.68 | 2019 | |
| Genentech USA, INC. | $149.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $140.54 | 2019-2021 | |
| Exelixis INC. | $132.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.20 | 2019 | |
| Tersera Therapeutics LLC | $123.18 | 2019 | |
| Array Biopharma INC | $108.56 | 2019 | |
| Janssen Scientific Affairs, LLC | $105.81 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $103.67 | 2020 | |
| Jazz Pharmaceuticals INC. | $100.89 | 2019 | |
| Seagen INC. | $99.55 | 2019 | |
| Stemline Therapeutics INC. | $62.25 | 2025 | Orserdu |
| Eisai INC. | $40.86 | 2019 | |
| Gilead Sciences, INC. | $33.48 | 2019 | |
| Incyte Corporation | $31.64 | 2019 | |
| Merck Sharp & Dohme LLC | $24.30 | 2025 | Lynparza, Keytruda |
| Abbvie INC. | $22.98 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $20.81 | 2019 | |
| Celgene Corporation | $18.17 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.76 | 2019 | |
| Taiho Oncology, INC. | $11.72 | 2019 | |
| Cardinal Health 414 LLC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nusrat Jahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.